一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 検索用
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集 全文PDF

Abstract

Full Text of PDF Full Text of PDF (591k)
Article in Japanese

Case Report

A case of pazopanib-induced lung injury diagnosed on readministration of the drug

Yutaka Takahara  Keisuke Nakase  Masatoshi Saito  Shiro Mizuno  Kazuhiro Osanai  Hirohisa Toga 

Department of Respiratory Medicine, Kanazawa Medical University

ABSTRACT

A 67-year-old man underwent nephrectomy for renal cell carcinoma in July 2014. He began pazopanib treatment for pulmonary metastases from renal cell carcinoma in September 2015.
After five months’ administration of pazopanib, he developed cough and was admitted to our hospital because a chest computed tomography (CT) scan showed ground-glass opacity in both lungs. After admission, levofloxacin was administered intravenously and pazopanib discontinued. Bronchoalveolar lavage was performed two days after cessation of the pazopanib administration, and analysis of bronchoalveolar lavage fluid showed an increased percentage of eosinophils. Seven days after admission, chest CT scan showed that the airspace opacification had improved. However, nine months later a urologist prescribed pazopanib a second time because of further growth in pulmonary metastases from the renal cell carcinoma. Three months later, the man was admitted to our hospital because of bilateral abnormal lung shadowing. After cessation of pazopanib, his symptoms and the ground-glass opacities in his bilateral lung fields improved spontaneously. Consequently, he was diagnosed with drug-induced lung injury caused by pazopanib. The possibility that drug-induced lung injury can be caused by pazopanib must be borne in mind.

KEYWORDS

Drug-induced lung injury  Pazopanib  Readministration 

Received 25 Apr 2017 / Accepted 7 Aug 2017

AJRS, 6(6): 468-472, 2017

Google Scholar